METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4-b]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS
申请人:Novartis AG
公开号:US20210387995A1
公开(公告)日:2021-12-16
The present disclosure provides for a compound according to formula (I)
or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, and early repolarization syndrome.
[EN] METHYL (R) -2- (FLUOROMETHYL) -5-OXO-4-PHENYL-4, 5, 6, 7-TETRAHYDRO-1H-CYCLOPENTA [B] PYRIDINE-3-CARBOXYLATE AND METHYL (R) -2- (FLUOROMETHYL) -5-OXO-4-PHENYL-1, 4, 5, 7-TETRAHYDROFURO [3, 4-B] PYRIDINE-3-CARBOXYLATE AS CAV1.2 ACTIVATORS<br/>[FR] MÉTHYL(R)-2-(FLUOROMÉTHYL)-5-OXO-4-PHÉNYL-4,5,6, 7-TÉTRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATE ET MÉTHYL(R)-2-(FLUOROMÉTHYL)-5-OXO-4-PHÉNYL-1,4,5,7-TÉTRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE UTILISÉS EN TANT QU'ACTIVATEURS DE CAV1.2
申请人:NOVARTIS AG
公开号:WO2021253180A1
公开(公告)日:2021-12-23
Provided herein is a compound according to formula (I) or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.
Methods and compositions for producing pancreatic beta cells
申请人:The Regents of the University of California
公开号:US11332716B2
公开(公告)日:2022-05-17
Compositions and methods of producing mammalian cell populations that include a high proportion of pancreatic beta cells are described herein. Such cell populations are useful for treatment of diabetes. Also provided are materials and methods for the direct differentiation of stem cells, such as embryonic stem cells, into functional pancreatic beta cells. The disclosure provides the benefit of direct differentiation, which results in the production of functional pancreatic beta cells efficiently and at low cost.